Intalight™ Receives CE Mark for Its Progressive DREAM OCT™ Swept Source Imaging
SAN JOSE, Calif. and SHANGHAI, May 15, 2025 /CNW/ -- Intalight™, a company that develops advanced ophthalmic technologies and a leader in Optical Coherence Tomography (OCT) today announced it has received CE mark for its DREAM OCT™ platform.
The CE mark serves as approval by the European Union (EU) to commercialize DREAM OCT, the newest version of OCT. DREAM stands for: Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging capabilities. The imaging platform provides the highest quality OCT images currently on the market.
"Intalight is incredibly proud to receive CE mark approval in Europe for our DREAM OCT," said Intalight chairman and Founder, Shawn Peng. "This achievement allows us to provide ophthalmologists in Europe with state-of-the-art technology that delivers improved results for their patients."
DREAM OCT is able to cover an ultrawide field single scan which delivers a 130° OCTA image. DREAM OCT™ swept-source 12 mm super-depth scanning allows superior imaging of the choroid and retina, and a large portion of the vitreous space. The super-depth anterior scanning capabilities achieves 16.2 mm (in air), allowing for the complete anterior segment from the cornea to the anterior part of the vitreous to be scanned in only one scan. The longer wavelength allows for superior penetration through opacities in either lens or vitreous.
"Over the past few years, we've heard from eye care professionals that they need a solution that gets them over the imaging finish line with speed, accuracy and depth," said Intalight CEO and Co-Founder, Bing Li. "DREAM OCT delivers a full set of imaging modalities for the most challenging clinical and research applications for the retina and outperforms everything else HCP's know."
Using ultra-wide swept-source technology, DREAM OCT was developed to address the needs of retina specialists, comprehensive ophthalmologists and their patients with highly-detailed imaging capabilities for improved care and results. Currently, more than 160 peer-reviewed papers have utilized findings from DREAM OCT devices.
"This is such exciting news for Intalight that there's no more waiting in Europe, and we look forward to being able to provide this innovative solution in the US," remarked Intalight Chief Commercial Officer, Joe Garibaldi. "We look forward to continuing to grow our prestigious network of global institutions and ophthalmologists with our recent CE approval and eventually our FDA approval."
As the clinically validated leader of ultra-wide field OCTA, Intalight is currently collaborating with the top retina academic institutions and retina private practices in the United States, Europe, and Asia.
About Intalight
Intalight Inc. was founded by a group of scientists and industry veterans of Silicon Valley with a core mission to develop the most advanced ophthalmic technologies. There are now three sites in Silicon Valley, Shanghai, and Luoyang. Intalight's Swept-Source Optical Coherence Tomography (OCT) device combines Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate lesion detection and Multimodal imaging capabilities, and is abbreviated as DREAM OCT™. The powerful imaging device has become an indispensable tool for many ophthalmologists in not only their daily clinical use but also their exploration of the research frontiers. To learn more about Intalight and DREAM OCT, please visit our website at https://www.intalight.com and follow us on LinkedIn and Facebook.
View original content to download multimedia:https://www.prnewswire.com/news-releases/intalight-receives-ce-mark-for-its-progressive-dream-oct-swept-source-imaging-302454390.html
SOURCE Intalight Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2025/15/c3929.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Public Advisory - Two lots of Seasonale birth control recalled due to extra placebo pills
OTTAWA, ON, June 4, 2025 /CNW/ - Summary Product: Seasonale (0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol) (DIN 02296659) Issue: Health products – Product quality What to do: Do not skip doses or stop taking Seasonale. If your package contains placebo (white) pills in tray 1 or 2 of the blister cards, do not take them and return the product to your pharmacy for a replacement or alternative product. If you cannot get to a pharmacy right away, take the next active (pink) pill in the proper order as noted in the instructions until you are able to contact your pharmacist and obtain a replacement or alternative product. Affected products Product DIN Lot Expiry Seasonale (0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol) 02296659 100059661 100069150 31-Jan-2026 30-Sep-2026 IssueTeva Canada Ltd. is recalling two lots of Seasonale prescription birth control after receiving a complaint that a package contained an extra row of placebo (white) pills where there should be none. Taking placebo pills instead of active (pink) pills may reduce the effectiveness of the product and could lead to an unintended pregnancy. As shown in Photo 1, Seasonale pills come packaged in a dispenser containing a 13-week (91-day) supply divided into three blister cards, each placed on its own tray: Trays 1 and 2 each hold a blister card with 28 active (pink) pills. Tray 3 holds a blister card with 35 pills: 28 active (pink) pills and 7 placebo (white) pills. Photo 2 shows three blister cards as well, but the tray 2 (middle blister card) contains an extra row of placebo (white) pills where there should be none. Seasonale should be taken daily unless otherwise directed by your prescriber to prevent pregnancy. Taking the pills in the proper order, according to the instructions that accompany the product, is important for preventing pregnancy. Taking a placebo (white) pill out of order could lead to unplanned pregnancy and other side effects, including spotting and irregular bleeding. Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventive actions to prevent this issue from reoccurring. The Department will inform the public if any new health risks are identified. What you should do Do not stop taking Seasonale. Do not skip taking any active (pink) pills until the very last row of tray 3 (which is the placebo [white] pills). Check your package. If it contains placebo (white) pills in tray 1 or 2 of the blister cards, do not take them, and return the product to your pharmacy for a replacement or alternative product. If you cannot get to a pharmacy right away, take the next active (pink) pill in the proper order as noted in the instructions until you are able to contact your pharmacist and obtain a replacement or alternative product. If you are unsure whether your package contains the correct pills, talk to your pharmacist. If you took a placebo (white) pill instead of an active (pink) pill from trays 1 or 2, or if you are unsure, you should also use another method of non-hormonal back-up contraception (such as condoms) and consult with your health care professional. Talk to a health care professional if you have any other questions or concerns about your birth control product. Contact Teva Canada Ltd. by calling toll-free at 1-800-268-4127, Option 3, or by email at druginfo@ if you have questions about this recall. Report any health product-related side effects or complaints to Health Canada. Également disponible en français SOURCE Health Canada (HC) View original content to download multimedia: Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
Public Advisory - Two lots of Seasonale birth control recalled due to extra placebo pills
OTTAWA, ON, June 4, 2025 /CNW/ - Summary Product: Seasonale (0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol) (DIN 02296659) Issue: Health products – Product quality What to do: Do not skip doses or stop taking Seasonale. If your package contains placebo (white) pills in tray 1 or 2 of the blister cards, do not take them and return the product to your pharmacy for a replacement or alternative product. If you cannot get to a pharmacy right away, take the next active (pink) pill in the proper order as noted in the instructions until you are able to contact your pharmacist and obtain a replacement or alternative product. Affected products Product DIN Lot Expiry Seasonale (0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol) 02296659 100059661 100069150 31-Jan-2026 30-Sep-2026 IssueTeva Canada Ltd. is recalling two lots of Seasonale prescription birth control after receiving a complaint that a package contained an extra row of placebo (white) pills where there should be none. Taking placebo pills instead of active (pink) pills may reduce the effectiveness of the product and could lead to an unintended pregnancy. As shown in Photo 1, Seasonale pills come packaged in a dispenser containing a 13-week (91-day) supply divided into three blister cards, each placed on its own tray: Trays 1 and 2 each hold a blister card with 28 active (pink) pills. Tray 3 holds a blister card with 35 pills: 28 active (pink) pills and 7 placebo (white) pills. Photo 2 shows three blister cards as well, but the tray 2 (middle blister card) contains an extra row of placebo (white) pills where there should be none. Seasonale should be taken daily unless otherwise directed by your prescriber to prevent pregnancy. Taking the pills in the proper order, according to the instructions that accompany the product, is important for preventing pregnancy. Taking a placebo (white) pill out of order could lead to unplanned pregnancy and other side effects, including spotting and irregular bleeding. Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventive actions to prevent this issue from reoccurring. The Department will inform the public if any new health risks are identified. What you should do Do not stop taking Seasonale. Do not skip taking any active (pink) pills until the very last row of tray 3 (which is the placebo [white] pills). Check your package. If it contains placebo (white) pills in tray 1 or 2 of the blister cards, do not take them, and return the product to your pharmacy for a replacement or alternative product. If you cannot get to a pharmacy right away, take the next active (pink) pill in the proper order as noted in the instructions until you are able to contact your pharmacist and obtain a replacement or alternative product. If you are unsure whether your package contains the correct pills, talk to your pharmacist. If you took a placebo (white) pill instead of an active (pink) pill from trays 1 or 2, or if you are unsure, you should also use another method of non-hormonal back-up contraception (such as condoms) and consult with your health care professional. Talk to a health care professional if you have any other questions or concerns about your birth control product. Contact Teva Canada Ltd. by calling toll-free at 1-800-268-4127, Option 3, or by email at druginfo@ if you have questions about this recall. Report any health product-related side effects or complaints to Health Canada. Également disponible en français SOURCE Health Canada (HC) View original content to download multimedia:
Yahoo
6 hours ago
- Yahoo
OceanaGold Reports Voting Results from its 2025 Annual General and Special Meeting
VANCOUVER, BC, June 4, 2025 /CNW/ - OceanaGold Corporation (TSX: OGC), (TSX: OTCQX) (TSX: OCANF) ("OceanaGold" or the "Company") is pleased to report the voting results from the Company's 2025 Annual General and Special Meeting of Shareholders (the "Annual Meeting") held today. A total of 538,458,035 common shares were voted at the meeting, representing 77.12% of the votes attached to all outstanding common shares. Shareholders voted in favour of each of the items of business at the Annual Meeting as follows: Election of Directors Resolutions electing each of the director nominees listed in OceanaGold's Management Information Circular dated April 23, 2025 as directors of the Company were passed by ordinary resolution. Detailed results of the vote for each director are set out in the table below: Directors Votes For % Votes Withheld / Abstain % Paul Benson 393,936,966 79.79 99,784,006 20.21 Ian M. Reid 488,729,245 98.99 4,991,727 1.01 Craig J. Nelsen 491,026,458 99.45 2,694,514 0.55 Sandra M. Dodds 482,121,086 97.65 11,599,886 2.35 Alan N. Pangbourne 490,403,457 99.33 3,317,515 0.67 Linda M. Broughton 491,015,000 99.45 2,705,972 0.55 Stefanie E. Loader 493,423,819 99.94 297,153 0.06 Gerard M. Bond 493,434,771 99.94 286,201 0.06 Share Consolidation A special resolution approving the consolidation of all issued and outstanding common shares of the Company on a consolidation ratio of up to three (3) pre-consolidation common shares for one (1) post-consolidation common share (the "Consolidation") was passed. Votes For % Votes Against % 536,892,725 99.71 1,565,307 0.29 The Company is exploring the benefits of a dual listing of its common shares on a major U.S. exchange, including the New York Stock Exchange, for a potential listing in the first half of 2026. The Company believes a U.S. listing could lead to increased interest by a wider audience of potential investors and result in increased marketability and trading liquidity. The principal reason for the Consolidation is to raise the per share trading price of the common shares in order to better comply with minimum trading price requirements of such exchanges. Subject to approval by the Toronto Stock Exchange, OceanaGold expects the Consolidation to be effective on or around June 23, 2025, and intends to issue a detailed press release to provide a further update and final details on the Consolidation. Appointment of Auditor A resolution appointing PricewaterhouseCoopers LLP (PWC Canada) as the auditor of the Company for the ensuing year and authorizing the board of the Company to fix their remuneration was passed. Votes For % Votes Withheld / Abstain % 508,912,534 94.51 29,545,500 5.49 Advisory Vote on Executive Compensation A non-binding resolution on the Company's approach to executive compensation was passed. Votes For % Votes Against % 480,384,783 97.30 13,336,189 2.70 Virtual-Only Meetings A resolution approving the Company to hold the 2026 Annual General Meeting of Shareholders exclusively in a virtual-only format was passed. Votes For % Votes Against % 325,303,717 65.89 168,417,253 34.11 Amendments to the Company's Articles A special resolution approving amendments to the Company's articles was passed. Votes For % Votes Against % 491,746,774 99.60 1,974,197 0.40 About OceanaGold OceanaGold is a growing intermediate gold and copper producer committed to safely and responsibly maximizing the generation of Free Cash Flow from our operations and delivering strong returns for our shareholders. We have a portfolio of four operating mines: the Haile Gold Mine in the United States of America; Didipio Mine in the Philippines; and the Macraes and Waihi operations in New Zealand. Cautionary Statement for Public Release This press release contains certain "forward-looking statements" and "forward-looking information" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws which may include, but is not limited to, statements with respect to the Company being listed on a major U.S. exchange, including such dual listing leading to increased interest by a wider audience of potential investors, increased marketability and trading liquidity and the expected timing for such listing, and the anticipated timing and effects of the completion of the Consolidation. Forward-looking statements and information relate to future performance and reflect the Company's expectations regarding the generation of Free Cash Flow, execution of business strategy, future growth, future production, estimated costs, results of operations, business prospects and opportunities of OceanaGold and its related subsidiaries. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "expects" or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "estimates" or "intends", or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those expressed in the forward-looking statements. They include, among others, those risk factors identified in the Company's most recent Annual Information Form prepared and filed with securities regulators which is available on SEDAR+ at under the Company's name and on the Company's website. There are no assurances the Company can fulfil forward-looking statements. Such forward-looking statements are only predictions based on current information available to management as of the date that such predictions are made; actual events or results may differ materially as a result of risks facing the Company, some of which are beyond the Company's control. Although the Company believes that any forward-looking statements contained in this press release is based on reasonable assumptions, readers cannot be assured that actual outcomes or results will be consistent with such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements and information, whether as a result of new information, events or otherwise, except as required by applicable securities laws. View original content to download multimedia: SOURCE OceanaGold Corporation View original content to download multimedia: Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
